D
Foghorn Therapeutics Inc. FHTX
$4.47 -$0.115-2.51%
Recommendation
Sell
Prev Close
$4.58
Volume
29,596
Avg Vol (90D)
150,859
Market Cap
$254.70M
Dividend & Yield
--
52-Week Range
$3.86 - $10.25
P/E (TTM)
--
EPS (TTM)
-$1.65
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
HC Wainwright Reaffirms Buy Rating for Foghorn Therapeutics (NASDAQ:FHTX)
3/9/2025 - Ticker Report
Foghorn Therapeutics' (FHTX) "Buy" Rating Reaffirmed at HC Wainwright
3/8/2025 - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS
3/7/2025 - MarketBeat
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
3/6/2025 - Zacks Investment Research
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
3/6/2025 - GuruFocus
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
3/6/2025 - Globe Newswire
Foghorn Therapeutics (FHTX, $4.32) price exceeded its 50-day Moving Average on March 03, 2025
3/4/2025 - Tickeron - Stocks
Foghorn Therapeutics (FHTX, $4.85) price moved above its 50-day Moving Average on February 28, 2025
3/1/2025 - Tickeron - Stocks
Foghorn Therapeutics (FHTX, $4.63) price exceeded its 50-day Moving Average on February 27, 2025
2/28/2025 - Tickeron - Stocks
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
2/27/2025 - Zacks Investment Research
Foghorn Therapeutics (FHTX, $5.01) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 26, 2025
2/27/2025 - Tickeron - Stocks
Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday
2/27/2025 - MarketBeat
Foghorn Therapeutics (FHTX, $5.1) entered Downtrend as Momentum indicator drops below 0 level on Feb 25, 2025
2/26/2025 - Tickeron - Stocks
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
2/25/2025 - GuruFocus
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
2/25/2025 - Globe Newswire
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Brokerages
2/24/2025 - MarketBeat
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking
2/23/2025 - Simply Wall St
Foghorn Therapeutics (FHTX, $5.87) RSI Indicator left the overbought zone on February 19, 2025
2/20/2025 - Tickeron - Stocks
Foghorn Therapeutics Breaks Above 200-Day Moving Average - Bullish for FHTX
2/18/2025 - Market News Video
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Significant Growth in Short Interest
2/18/2025 - Ticker Report
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short Interest
2/18/2025 - MarketBeat
Foghorn Therapeutics (FHTX, $5.52) RSI Indicator left the overbought zone on February 12, 2025
2/13/2025 - Tickeron - Stocks
FMR LLC Reduces Stake in Foghorn Therapeutics Inc
2/12/2025 - GuruFocus
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
2/11/2025 - Zacks Investment Research
We Did The Math UWM Can Go To $52
2/11/2025 - ETF Channel
Income Statement
Total Revenue (TTM)
$22.60M
EBITDA (TTM)
-$97.17M
EBIT (TTM)
-$100.29M
Net Income (TTM)
-$86.62M
Balance Sheet
Total Assets (Q)
$283.98M
Total Debt (Q)
$37.13M
Total Liabilities (Q)
$329.51M
Book Value Per Share (Q)
-$0.8189
Cash Flow
Cash from Operations (TTM)
-$100.41M
Cash from Investing (TTM)
-$29.90M
Cash from Financing (TTM)
$105.43M
Net Change in Cash (TTM)
-$24.88M
Filings
Filing Date
Thursday, March 6, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.88
7-Day Total Return
1.71%
30-Day Total Return
12.19%
60-Day Total Return
-22.75%
90-Day Total Return
-44.47%
Year to Date Total Return
-2.72%
1-Year Total Return
-33.95%
2-Year Total Return
-14.30%
3-Year Total Return
-58.31%
5-Year Total Return
--
52-week Low
Jan 29, 2025 - $3.86
52-week High
Sep 18, 2024 - $10.25
Valuation
Market Cap
$254.70M - Micro Cap
Enterprise Value
$48.09M
Price/Sales (TTM)
12.74
Price/Book (Q)
-5.59
Dividends and Shares
Shares Outstanding
62.87M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
foghorntx.com
Phone Number
617 586 3100
Address
500 Technology Square
Cambridge, MA 02139
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin... more
NASDAQ 03/13/2025 12:52PM Eastern Quotes delayed
Weiss Ratings